Payment overview · 2025
General Payments
$477.20
20 reported records · 12 companies
Healthcare provider profile · identity verified
Sadiq Mandilawi, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · LA VERNE, CA · NPI 1295716736
Verified facts
What the public records show
CMS Open Payments records show Sadiq Mandilawi, MD received $477.20 in general payments during 2025 across 20 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $95.24 | 20.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.19 | 15.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.79 | 12.9% | 3 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $51.91 | 10.9% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $49.52 | 10.4% | 2 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.94 | 4.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.21 | 4.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.48 | 4.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.63 | 4.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.41 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.36 | 4.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.52 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $444.93 | 19 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $95.24 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.19 | 3 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $61.79 | 3 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $51.91 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $49.52 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.92 | 2 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 340 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
340 | 65 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Jardiance | Empagliflozin | 412 | 101 |
| Ozempic | Semaglutide | 340 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 87 |
| Trulicity | Dulaglutide | 255 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 238 | 73 |
| Simvastatin | Simvastatin | 196 | 55 |
| Metformin Hcl | Metformin Hcl | 189 | 58 |
| Metformin Hcl Er | Metformin Hcl | 172 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 57 |
| Losartan Potassium | Losartan Potassium | 157 | 48 |
| Nateglinide | Nateglinide | 152 | 51 |
| Gabapentin | Gabapentin | 107 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 34 |
| Mounjaro | Tirzepatide | 95 | 22 |
| Repaglinide | Repaglinide | 94 | 32 |
| Omeprazole | Omeprazole | 90 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 84 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 81 | 24 |
| Myrbetriq | Mirabegron | 81 | 13 |
| Farxiga | Dapagliflozin Propanediol | 80 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 80 | 25 |
| Allopurinol | Allopurinol | 75 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 72 | 34 |
| Valsartan | Valsartan | 70 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 19 |
| Famotidine | Famotidine | 65 | 24 |
| Carvedilol | Carvedilol | 54 | 14 |
| Ezetimibe | Ezetimibe | 53 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 16 |
| Furosemide | Furosemide | 51 | 15 |
| Lisinopril | Lisinopril | 51 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | 17 |
| Humalog | Insulin Lispro | 47 | 11 |
| Acarbose | Acarbose | 44 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Cilostazol | Cilostazol | 42 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | 11 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | 11 |
| Ibuprofen | Ibuprofen | 31 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | 11 |
| Novolog Flexpen | Insulin Aspart | 30 | 11 |
| Methimazole | Methimazole | 28 | suppressed |
| Baqsimi | Glucagon | 27 | 21 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Repatha Syringe | Evolocumab | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 13 |
| Eliquis | Apixaban | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Prolia | Denosumab | 16 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Teriparatide | Teriparatide | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $477.20 · 20 records | SANOFI-AVENTIS U.S. LLC | AIRSUPRA, FREESTYLE LIBRE 3, Korlym, Omnipod, Ozempic, REZDIFFRA, Rybelsus, STRENSIQ, TEPEZZA, TRYNGOLZA, TZIELD, UBRELVY, Yorvipath | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error